First phase I trial of influenza A virus H1N1 vaccine in Singapore.
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2014
At a glance
- Drugs Qb Flu (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Cytos Biotechnology
- 01 Feb 2014 Status changed from active, no longer recruiting to completed.
- 29 Jan 2014 Results have been reported in a Cytos Biotechnology and Singapore Agency for Science, Technology and research media release.
- 29 Jan 2014 Primary endpoint 'Immunological-response' (Immunogenicity as demonstrated by seroconversion based on haemaglutination inhibition titres according to FDA criteria) has been met according a Cytos Biotechnology media release.